Guangzhou Curegenix

Curegenix is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapies that target the Wnt signaling pathway for the treatment of cancer and fibrotic diseases. The company's lead program, CGX1321, is a potent and selective small molecule inhibitor of Porcupine, an enzyme essential for the secretion and function of all Wnt proteins. Curegenix is currently evaluating CGX1321 in Phase 1/2 clinical trials for patients with advanced solid tumors, particularly those with specific genetic alterations in the Wnt pathway such as RSPO fusions. Headquartered in Guangzhou, China, with R&D facilities in the San Francisco Bay Area, the company leverages its deep expertise in Wnt biology to address significant unmet medical needs in oncology.